{"id":305481,"date":"2025-07-14T14:16:42","date_gmt":"2025-07-14T14:16:42","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/cvs-stock-dividend-history-2\/"},"modified":"2025-07-14T14:16:42","modified_gmt":"2025-07-14T14:16:42","slug":"cvs-stock-dividend-history","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/","title":{"rendered":"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":250024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16],"tags":[28,45,44],"class_list":["post-305481","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-data","tag-investment","tag-stock","tag-strategy"],"acf":{"h1":"CVS Hisse Senedi Temett\u00fc Ge\u00e7mi\u015fi","h1_source":{"label":"H1","type":"text","formatted_value":"CVS Hisse Senedi Temett\u00fc Ge\u00e7mi\u015fi"},"description":"Kapsaml\u0131 CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi analizi ile ayr\u0131nt\u0131l\u0131 getiri e\u011filimleri ve b\u00fcy\u00fcme modelleri. Pocket Option ile temett\u00fc getirilerini nas\u0131l maksimize edece\u011finizi \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Kapsaml\u0131 CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi analizi ile ayr\u0131nt\u0131l\u0131 getiri e\u011filimleri ve b\u00fcy\u00fcme modelleri. Pocket Option ile temett\u00fc getirilerini nas\u0131l maksimize edece\u011finizi \u00f6\u011frenin."},"intro":"Bu derinlemesine analiz, gelir odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in de\u011ferli bilgiler sunarak CVS Health'in temett\u00fc ge\u00e7mi\u015fini inceliyor. \u0130ster bir emeklilik portf\u00f6y\u00fc olu\u015fturuyor olun, ister pasif gelir kaynaklar\u0131 ar\u0131yor olun, CVS hisse senedi temett\u00fc ge\u00e7mi\u015fini anlamak, g\u00fcn\u00fcm\u00fcz\u00fcn karma\u015f\u0131k finansal piyasas\u0131nda bilin\u00e7li yat\u0131r\u0131m kararlar\u0131 alman\u0131za yard\u0131mc\u0131 olacakt\u0131r.","intro_source":{"label":"Intro","type":"text","formatted_value":"Bu derinlemesine analiz, gelir odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in de\u011ferli bilgiler sunarak CVS Health'in temett\u00fc ge\u00e7mi\u015fini inceliyor. \u0130ster bir emeklilik portf\u00f6y\u00fc olu\u015fturuyor olun, ister pasif gelir kaynaklar\u0131 ar\u0131yor olun, CVS hisse senedi temett\u00fc ge\u00e7mi\u015fini anlamak, g\u00fcn\u00fcm\u00fcz\u00fcn karma\u015f\u0131k finansal piyasas\u0131nda bilin\u00e7li yat\u0131r\u0131m kararlar\u0131 alman\u0131za yard\u0131mc\u0131 olacakt\u0131r."},"body_html":"<div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>CVS Health'\u0131n Temett\u00fc Program\u0131n\u0131n Evrimi<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi, m\u00fctevaz\u0131 ba\u015flang\u0131\u00e7lardan 2024 y\u0131l\u0131na kadar hisse ba\u015f\u0131na 0.665 dolar\u0131 a\u015fan \u00fc\u00e7 ayl\u0131k \u00f6demelere d\u00f6n\u00fc\u015ferek yirmi y\u0131l\u0131 a\u015fk\u0131n bir s\u00fcreyi kaps\u0131yor. B\u00f6lgesel bir eczane zincirinden sa\u011fl\u0131k hizmetleri devine d\u00f6n\u00fc\u015fen \u015firketin yolculu\u011fu, hissedar getirilerine y\u00f6nelik geli\u015fen yakla\u015f\u0131m\u0131n\u0131 do\u011frudan yans\u0131t\u0131yor ve temett\u00fc yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in de\u011ferli bir vaka \u00e7al\u0131\u015fmas\u0131 haline geliyor.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>CVS, temett\u00fc \u00f6demelerini sat\u0131n almalar, bor\u00e7 y\u00f6netimi ve geni\u015fleme ile dengeleyerek sermaye tahsis stratejisindeki \u00f6nceliklerini ortaya koyuyor. Bu dengeli yakla\u015f\u0131m, CVS hisse senedi temett\u00fc getirisi e\u011filiminde, keyfi \u00f6deme politikalar\u0131ndan ziyade stratejik i\u015f kararlar\u0131n\u0131 yans\u0131tan belirgin a\u015famalar yaratm\u0131\u015ft\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option'daki finansal analistler, CVS'nin i\u015f modelindeki bu stratejik de\u011fi\u015fimlerin temett\u00fc ge\u00e7mi\u015findeki belirgin a\u015famalarla do\u011frudan ili\u015fkili oldu\u011funu belirtiyor. \u015eirketin eczane perakendecisinden entegre sa\u011fl\u0131k hizmeti sa\u011flay\u0131c\u0131s\u0131na d\u00f6n\u00fc\u015f\u00fcm\u00fc, \u00fc\u00e7 farkl\u0131 temett\u00fc d\u00f6nemi yaratm\u0131\u015ft\u0131r: b\u00fcy\u00fcme (2010-2016), konsolidasyon (2017-2021) ve \u00f6l\u00e7\u00fcl\u00fc geni\u015fleme (2022-g\u00fcn\u00fcm\u00fcz).<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Tarihsel Perspektif: CVS Temett\u00fc B\u00fcy\u00fcme E\u011frisi<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>2010 ve 2016 y\u0131llar\u0131 aras\u0131nda, CVS \u00fc\u00e7 ayl\u0131k temett\u00fcs\u00fcn\u00fc bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131 %24.8 ile 0.0875 dolardan hisse ba\u015f\u0131na 0.50 dolara \u00e7\u0131kard\u0131. Bu agresif b\u00fcy\u00fcme a\u015famas\u0131, \u015firketin d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc Aetna sat\u0131n al\u0131m\u0131n\u0131 ger\u00e7ekle\u015ftirirken temett\u00fcs\u00fcn\u00fc be\u015f y\u0131l boyunca \u00fc\u00e7 ayda bir 0.50 dolarda dondurdu\u011fu 2017 y\u0131l\u0131nda aniden sona erdi.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>D\u00f6nem<\/th><th>Temett\u00fc Stratejisi<\/th><th>CAGR<\/th><th>Ana \u0130\u015f Olaylar\u0131<\/th><\/tr><\/thead><tbody><tr><td>2010-2016<\/td><td>Agresif b\u00fcy\u00fcme<\/td><td>%24.8<\/td><td>Caremark entegrasyonu, perakende geni\u015fleme<\/td><\/tr><tr><td>2017-2021<\/td><td>\u00dc\u00e7 ayda bir 0.50 dolarda temett\u00fc dondurma<\/td><td>%0<\/td><td>69 milyar dolarl\u0131k Aetna sat\u0131n al\u0131m\u0131, bor\u00e7 azaltma odakl\u0131<\/td><\/tr><tr><td>2022-2023<\/td><td>Temett\u00fc b\u00fcy\u00fcmesinin yeniden ba\u015flamas\u0131<\/td><td>%10.0<\/td><td>Sat\u0131n alma sonras\u0131 entegrasyon, 9.8 milyar dolarl\u0131k bor\u00e7 azaltma<\/td><\/tr><tr><td>2024-G\u00fcn\u00fcm\u00fcz<\/td><td>Orta derecede b\u00fcy\u00fcme modeli<\/td><td>%9.9<\/td><td>Sa\u011fl\u0131k hizmeti sunum modeli d\u00f6n\u00fc\u015f\u00fcm\u00fc<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Be\u015f y\u0131ll\u0131k temett\u00fc dondurmas\u0131, do\u011frudan CVS'nin 2018'de Aetna'y\u0131 69 milyar dolara sat\u0131n almas\u0131yla \u00e7ak\u0131\u015ft\u0131. Bu d\u00f6nemde, CVS bilan\u00e7osunu hafifletmeye \u00f6ncelik vererek, borcunu yakla\u015f\u0131k 13.3 milyar dolar azalt\u0131rken hissedar \u00f6demelerini b\u00fcy\u00fctmek yerine korudu. Bu stratejik karar, entegrasyon d\u00f6neminde sermayeyi korudu\u011fu i\u00e7in mali a\u00e7\u0131dan ak\u0131ll\u0131ca oldu ve yat\u0131r\u0131mc\u0131 g\u00fcvenini zedeleyebilecek temett\u00fc kesintilerinden ka\u00e7\u0131n\u0131ld\u0131.<\/p><\/div><div class='po-container po-container_width_article-sm'><h3 class='po-article-page__title'>Son Temett\u00fc H\u0131zlanma A\u015famas\u0131<\/h3><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Ocak 2022'de, CVS temett\u00fc b\u00fcy\u00fcmesini \u00fc\u00e7 ayda bir %10 art\u0131\u015fla 0.55 dolara, ard\u0131ndan 2023'te %10 art\u0131\u015fla 0.605 dolara ve Ocak 2024'te %9.9 art\u0131\u015fla 0.665 dolara \u00e7\u0131kararak yeniden ba\u015flatt\u0131. Bu \u00fc\u00e7 y\u0131ll\u0131k h\u0131zlanma a\u015famas\u0131, daha \u00f6nce dondurulmu\u015f seviyeden %9.97 bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme sa\u011flad\u0131.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>\u00d6deme Tarihi<\/th><th>Hisse Ba\u015f\u0131na Temett\u00fc ($)<\/th><th>Y\u0131ll\u0131k Art\u0131\u015f (%)<\/th><th>Son 12 Ayl\u0131k EPS Kapsam\u0131<\/th><\/tr><\/thead><tbody><tr><td>Ocak 2022<\/td><td>$0.55<\/td><td>%10.0<\/td><td>3.13x<\/td><\/tr><tr><td>Ocak 2023<\/td><td>$0.605<\/td><td>%10.0<\/td><td>3.02x<\/td><\/tr><tr><td>Ocak 2024<\/td><td>$0.665<\/td><td>%9.9<\/td><td>3.01x<\/td><\/tr><tr><td>Beklenen Nisan 2025<\/td><td>$0.67 (tahmini)<\/td><td>~%0.75<\/td><td>3.37x (tahmini)<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>2025'te %0.75 b\u00fcy\u00fcmeye yava\u015flama, y\u00f6netimin eczane alan\u0131ndaki artan rekabet ve sa\u011fl\u0131k hizmetleri geri \u00f6deme bask\u0131lar\u0131 kar\u015f\u0131s\u0131nda temkinli g\u00f6r\u00fcn\u00fcm\u00fcn\u00fc yans\u0131t\u0131yor. 2023 4. \u00c7eyrek kazan\u00e7 \u00e7a\u011fr\u0131s\u0131nda, CFO Shawn Guertin, \"belirsiz piyasa ko\u015fullar\u0131\" ve \"stratejik esneklik gereksinimleri\"ni temett\u00fc b\u00fcy\u00fcme beklentilerini \u0131l\u0131ml\u0131la\u015ft\u0131rman\u0131n nedenleri olarak belirtti.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>CVS Hisse Senedi Temett\u00fc Getirisi Analizi: Ana Performans Metrikleri<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Mutlak temett\u00fc \u00f6demelerinin artmas\u0131na ra\u011fmen, CVS hisse senedi temett\u00fc getirisi, hisse fiyat\u0131 dalgalanmalar\u0131 nedeniyle 2019'da %3.81'den 2024'te %2.58'e d\u00fc\u015ft\u00fc. Bu ters ili\u015fki, ge\u00e7ici fiyat d\u00fc\u015f\u00fc\u015fleri s\u0131ras\u0131nda cazip giri\u015f noktalar\u0131n\u0131 belirleyebilen gelir yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in stratejik f\u0131rsatlar yarat\u0131r.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Y\u0131l<\/th><th>Ortalama Temett\u00fc Getirisi<\/th><th>Hisse Fiyat\u0131 Aral\u0131\u011f\u0131<\/th><th>Sekt\u00f6r Ortalama Getirisi<\/th><\/tr><\/thead><tbody><tr><td>2019<\/td><td>%3.81<\/td><td>$52-$77<\/td><td>%2.7<\/td><\/tr><tr><td>2020<\/td><td>%3.12<\/td><td>$52-$76<\/td><td>%2.9<\/td><\/tr><tr><td>2022<\/td><td>%2.31<\/td><td>$88-$111<\/td><td>%2.4<\/td><\/tr><tr><td>2024 (G\u00fcncel)<\/td><td>%2.58<\/td><td>$58-$77<\/td><td>%2.5<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>CVS hisse senedi temett\u00fc getirisi, eczane geri \u00f6deme oranlar\u0131 ve perakende bozulma konusundaki piyasa endi\u015feleri hisse fiyatlar\u0131n\u0131 55 dolar\u0131n alt\u0131na d\u00fc\u015f\u00fcrd\u00fc\u011f\u00fcnde 2019'da %3.81 ile zirveye ula\u015ft\u0131. Bunu ge\u00e7ici bir de\u011ferleme kopuklu\u011fu olarak tan\u0131yan yat\u0131r\u0131mc\u0131lar, hem ortalaman\u0131n \u00fczerinde gelir hem de 2021 sonlar\u0131nda 100 dolar aral\u0131\u011f\u0131na geri d\u00f6nd\u00fc\u011f\u00fcnde sermaye kazanc\u0131 sa\u011flad\u0131.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option'\u0131n temett\u00fc izleme ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar, CVS'nin getirisi tarihsel ortalamas\u0131n\u0131n \u00f6nemli \u00f6l\u00e7\u00fcde \u00fczerine \u00e7\u0131kt\u0131\u011f\u0131nda, potansiyel olarak cazip bir giri\u015f noktas\u0131n\u0131 belirleyebilir. \u015eu anda, %2.58'lik getiri, \u015firketin 5 y\u0131ll\u0131k ortalama getirisi olan %3.11'in %17 alt\u0131nda, bu da mevcut fiyatlarda \u0131l\u0131ml\u0131 ancak \u00e7ekici olmayan bir gelir de\u011feri \u00f6neriyor.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Kar\u015f\u0131la\u015ft\u0131rmal\u0131 Analiz: CVS Temett\u00fc Politikas\u0131 ve Sekt\u00f6r E\u015fleri<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>CVS'nin temett\u00fc yakla\u015f\u0131m\u0131, Walgreens gibi y\u00fcksek getirili, yava\u015f b\u00fcy\u00fcyen \u015firketler ile UnitedHealth gibi d\u00fc\u015f\u00fck getirili, agresif b\u00fcy\u00fcme modelleri aras\u0131nda stratejik bir orta yol i\u015fgal ediyor. Bu konumland\u0131rma, CVS'nin perakende eczane, sigorta ve sa\u011fl\u0131k hizmetleri alanlar\u0131n\u0131 kapsayan hibrit i\u015f modelini yans\u0131t\u0131yor.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>\u015eirket<\/th><th>G\u00fcncel Temett\u00fc Getirisi<\/th><th>5 Y\u0131ll\u0131k Temett\u00fc CAGR<\/th><th>\u00d6deme Oran\u0131<\/th><th>Temett\u00fc G\u00fcvenlik Skoru<\/th><\/tr><\/thead><tbody><tr><td>CVS Health<\/td><td>%2.58<\/td><td>%5.9<\/td><td>%30<\/td><td>85\/100 (\u00c7ok G\u00fcvenli)<\/td><\/tr><tr><td>Walgreens Boots Alliance<\/td><td>%4.7<\/td><td>%2.1<\/td><td>%40<\/td><td>55\/100 (G\u00fcvenli)<\/td><\/tr><tr><td>UnitedHealth Group<\/td><td>%1.6<\/td><td>%15<\/td><td>%33<\/td><td>95\/100 (\u00c7ok G\u00fcvenli)<\/td><\/tr><tr><td>Cardinal Health<\/td><td>%1.9<\/td><td>%1.3<\/td><td>%36<\/td><td>70\/100 (G\u00fcvenli)<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>CVS, yakla\u015f\u0131k %30 kazan\u00e7 oran\u0131yla, e\u015f grubu aras\u0131nda en muhafazakar \u00f6deme oranlar\u0131ndan birini koruyor. Bu oran, \u015firketin i\u015f d\u00f6n\u00fc\u015f\u00fcm\u00fcne ra\u011fmen \u015fa\u015f\u0131rt\u0131c\u0131 derecede istikrarl\u0131 kalm\u0131\u015f olup, hissedar getirilerini yeniden yat\u0131r\u0131m ihtiya\u00e7lar\u0131yla dengeleme konusunda disiplinli bir yakla\u015f\u0131m\u0131 g\u00f6steriyor. Ba\u011flam i\u00e7in, sa\u011fl\u0131k sekt\u00f6r\u00fc ortalama \u00f6deme oran\u0131 %38'dir, bu da CVS'nin finansal kaynaklar\u0131n\u0131 zorlamadan temett\u00fc art\u0131\u015flar\u0131 i\u00e7in ek kapasiteye sahip oldu\u011funu g\u00f6steriyor.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>CVS Temett\u00fc Kararlar\u0131n\u0131 Etkileyen Stratejik Fakt\u00f6rler<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi, form\u00fclsel art\u0131\u015flar yerine belirli i\u015f zorluklar\u0131na ve f\u0131rsatlar\u0131na verilen kas\u0131tl\u0131 yan\u0131tlar\u0131 yans\u0131t\u0131r. Bu stratejik itici g\u00fc\u00e7leri anlamak, yat\u0131r\u0131mc\u0131lar\u0131n gelecekteki temett\u00fc eylemlerini, tarihsel b\u00fcy\u00fcme oranlar\u0131n\u0131n basit bir ekstrapolasyonundan daha do\u011fru bir \u015fekilde tahmin etmelerine yard\u0131mc\u0131 olur.<\/p><\/div><div class='po-container po-container_width_article-sm article-content po-article-page__text'><ul class='po-article-page-list'><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Serbest nakit ak\u0131\u015f\u0131 \u00fcretimi: CVS'nin eczane operasyonlar\u0131, 2023'te 12.7 milyar dolar i\u015fletme nakit ak\u0131\u015f\u0131 \u00fcreterek sa\u011flam temett\u00fc kapsam\u0131 sa\u011flad\u0131<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Entegrasyon yat\u0131r\u0131mlar\u0131: Aetna sat\u0131n al\u0131m\u0131, 2018-2021 aras\u0131nda 2.3 milyar dolar entegrasyon maliyeti gerektirdi ve do\u011frudan temett\u00fc b\u00fcy\u00fcme kapasitesini etkiledi<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Sa\u011fl\u0131k hizmetleri geri \u00f6deme bask\u0131lar\u0131: Eczane fayda s\u0131k\u0131\u015fmas\u0131, 2020'den bu yana re\u00e7ete ba\u015f\u0131na marjlar\u0131 yakla\u015f\u0131k %3.5 azaltt\u0131<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Dijital d\u00f6n\u00fc\u015f\u00fcm: Teknoloji modernizasyonuna 2.8 milyar dolarl\u0131k yat\u0131r\u0131m, temett\u00fc dolar\u0131 ile rekabet ediyor<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Bor\u00e7 azaltma \u00f6ncelikleri: Net bor\u00e7, sat\u0131n alma sonras\u0131 73.6 milyar dolardan 2023'te 51.4 milyar dolara d\u00fc\u015ft\u00fc<\/li><\/ul><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>CVS hisse senedi temett\u00fc tarihindeki en \u00f6nemli d\u00f6nem, \u015firketin 69 milyar dolarl\u0131k Aetna sat\u0131n al\u0131m\u0131n\u0131 finanse etmek i\u00e7in temett\u00fc b\u00fcy\u00fcmesini tamamen durdurdu\u011fu 2017-2021 y\u0131llar\u0131 aras\u0131nda ger\u00e7ekle\u015fti. Bu be\u015f y\u0131ll\u0131k d\u00f6nemde, CVS bor\u00e7\/EBITDA oran\u0131n\u0131 4.7x'den 3.1x'e d\u00fc\u015f\u00fcr\u00fcrken temett\u00fcs\u00fcn\u00fc b\u00fcy\u00fctmek yerine korudu ve finansal istikrar\u0131 an\u0131nda hissedar getirilerinin \u00f6n\u00fcne koydu.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Stratejik Giri\u015fim<\/th><th>Yat\u0131r\u0131lan Sermaye<\/th><th>Temett\u00fc Etkisi<\/th><th>Uzun Vadeli Temett\u00fc Faydas\u0131<\/th><\/tr><\/thead><tbody><tr><td>MinuteClinic\/HealthHUB geni\u015flemesi<\/td><td>$1.2 milyar<\/td><td>~$0.03 temett\u00fc azaltma potansiyeli<\/td><td>2026'ya kadar y\u0131ll\u0131k 0.6 milyar dolar ek kazan\u00e7<\/td><\/tr><tr><td>Dijital sa\u011fl\u0131k yat\u0131r\u0131mlar\u0131<\/td><td>$2.8 milyar<\/td><td>~$0.07 temett\u00fc azaltma potansiyeli<\/td><td>2025'e kadar y\u0131ll\u0131k 1.2 milyar dolar maliyet tasarrufu<\/td><\/tr><tr><td>Eczane otomasyonu<\/td><td>$1.4 milyar<\/td><td>~$0.035 temett\u00fc azaltma potansiyeli<\/td><td>2026'ya kadar %0.8 marj geni\u015flemesi<\/td><\/tr><tr><td>Oak Street Health sat\u0131n al\u0131m\u0131<\/td><td>$10.6 milyar<\/td><td>~$0.25 temett\u00fc azaltma potansiyeli<\/td><td>2026'ya kadar 2 milyar dolar ek EBITDA<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option'daki analistler, her stratejik giri\u015fimin k\u0131sa vadeli temett\u00fc kapasitesini uzun vadeli temett\u00fc b\u00fcy\u00fcme potansiyeline kar\u015f\u0131 nas\u0131l etkiledi\u011fini nicel olarak belirleyen \u00f6zel bir CVS Temett\u00fc Kapasite Modeli geli\u015ftirdiler. Bu model, mevcut stratejik yat\u0131r\u0131mlar\u0131n \u00f6ng\u00f6r\u00fclen getirilerini sa\u011flamas\u0131 durumunda CVS'nin 2027'ye kadar y\u0131ll\u0131k %7-9 oran\u0131nda temett\u00fcs\u00fcn\u00fc s\u00fcrd\u00fcr\u00fclebilir bir \u015fekilde art\u0131rabilece\u011fini \u00f6ne s\u00fcr\u00fcyor.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>CVS Temett\u00fc Modellerinden Yararlanan Yat\u0131r\u0131mc\u0131 Stratejileri<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi, farkl\u0131 yat\u0131r\u0131mc\u0131 profilleri i\u00e7in belirli f\u0131rsatlar yarat\u0131r. Tarihsel analiz, belirli taktik yakla\u015f\u0131mlar\u0131n pasif temett\u00fc toplama stratejilerini s\u00fcrekli olarak geride b\u0131rakt\u0131\u011f\u0131n\u0131 ortaya koyuyor.<\/p><\/div><div class='po-container po-container_width_article-sm article-content po-article-page__text'><ul class='po-article-page-list'><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Getiri tetikleyici giri\u015f noktalar\u0131: Getiri %3.25'i a\u015ft\u0131\u011f\u0131nda sat\u0131n almak, tarihsel olarak %15.3 ortalama y\u0131ll\u0131k toplam getiri sa\u011flam\u0131\u015ft\u0131r<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Dondurma sonras\u0131 h\u0131zlanma: Temett\u00fc dondurma d\u00f6nemlerinde b\u00fcy\u00fcme yeniden ba\u015flamadan \u00f6nce birikim yapmak (2022-2023'te %17.8 getiri)<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Temett\u00fc yeniden yat\u0131r\u0131m optimizasyonu: Otomatik yeniden yat\u0131r\u0131m yerine fiyat zay\u0131fl\u0131\u011f\u0131 s\u0131ras\u0131nda se\u00e7ici DRIP<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Sekt\u00f6r rotasyonu: CVS getirisini di\u011fer sa\u011fl\u0131k temett\u00fc \u00f6deyenlerle kar\u015f\u0131la\u015ft\u0131rarak g\u00f6receli de\u011feri belirlemek<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Stratejik ortalama: Getiri-b\u00fcy\u00fcme oran\u0131 %0.4'\u00fc a\u015ft\u0131\u011f\u0131nda \u00fc\u00e7 ayl\u0131k bazda pozisyonlar olu\u015fturmak<\/li><\/ul><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Yat\u0131r\u0131mc\u0131 Profili<\/th><th>Optimal Strateji<\/th><th>Tarihsel Ba\u015far\u0131 \u00d6rne\u011fi<\/th><th>Ana Zamanlama G\u00f6stergesi<\/th><\/tr><\/thead><tbody><tr><td>Gelir odakl\u0131 emekli<\/td><td>Getiri tetikleyici al\u0131mlar<\/td><td>Mart 2020: %3.8 getiri giri\u015f noktas\u0131<\/td><td>Getiri &gt; %3.25<\/td><\/tr><tr><td>B\u00fcy\u00fcme yat\u0131r\u0131mc\u0131s\u0131<\/td><td>Temett\u00fc dondurma sonras\u0131 birikim<\/td><td>2021 4. \u00c7eyrek: Temett\u00fc art\u0131\u015f\u0131 \u00f6ncesi konumland\u0131rma<\/td><td>Y\u00f6netim temett\u00fc b\u00fcy\u00fcme sinyalleri<\/td><\/tr><tr><td>De\u011fer yat\u0131r\u0131mc\u0131s\u0131<\/td><td>Temett\u00fc b\u00fcy\u00fcmesine g\u00f6re fiyat\/kazan\u00e7<\/td><td>2019: P\/E s\u0131k\u0131\u015f\u0131rken temett\u00fc sabit kald\u0131<\/td><td>P\/E oran\u0131 5 y\u0131ll\u0131k ortalaman\u0131n alt\u0131nda<\/td><\/tr><tr><td>Toplam getiri optimizasyoncusu<\/td><td>Getiriye dayal\u0131 dinamik pozisyon boyutland\u0131rma<\/td><td>60 dolar\u0131n alt\u0131nda pozisyonu ikiye katlad\u0131, 90 dolar\u0131n \u00fczerinde azaltt\u0131<\/td><td>5 y\u0131ll\u0131k ortalamadan sapma<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>\u00d6ng\u00f6r\u00fclebilir gelire odaklanan yat\u0131r\u0131mc\u0131lar i\u00e7in, CVS hisse senedi temett\u00fcleri genellikle Ocak, Nisan, Temmuz ve Ekim aylar\u0131n\u0131n sonlar\u0131nda d\u00fc\u015fen ex-temett\u00fc tarihleriyle \u00fc\u00e7 ayl\u0131k \u00f6demeler sunar. \u00d6n\u00fcm\u00fczdeki d\u00f6rt tahmini ex-temett\u00fc tarihi 24 Ekim 2024; 23 Ocak 2025; 24 Nisan 2025; ve 24 Temmuz 2025 olup, \u00f6deme tarihleri yakla\u015f\u0131k iki hafta sonrad\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Gelecek G\u00f6r\u00fcn\u00fcm\u00fc: CVS Temett\u00fc E\u011frisi<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Mevcut finansal metrikler, y\u00f6netim rehberli\u011fi ve CVS hisse senedi temett\u00fc ge\u00e7mi\u015findeki tarihsel kal\u0131plara dayanarak, \u00f6n\u00fcm\u00fczdeki 3-5 y\u0131l i\u00e7in CVS'nin temett\u00fc b\u00fcy\u00fcmesi i\u00e7in \u00fc\u00e7 potansiyel senaryo \u00f6ng\u00f6rebiliriz:<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Senaryo<\/th><th>Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesi<\/th><th>\u00d6zel Kataliz\u00f6rler<\/th><th>Olas\u0131l\u0131k<\/th><\/tr><\/thead><tbody><tr><td>Temkinli Durum<\/td><td>%3-5<\/td><td>Eczane marj s\u0131k\u0131\u015fmas\u0131 &gt;%5, Medicare Advantage oran bask\u0131s\u0131<\/td><td>%30<\/td><\/tr><tr><td>Temel Durum<\/td><td>%7-9<\/td><td>Oak Street Health entegrasyonunun ba\u015far\u0131s\u0131, \u0131l\u0131ml\u0131 eczane faydalar\u0131n\u0131n istikrar\u0131<\/td><td>%50<\/td><\/tr><tr><td>Agresif Durum<\/td><td>%10-12<\/td><td>HealthHUB kar marj\u0131 %15'i a\u015farsa, de\u011fer bazl\u0131 bak\u0131m modelinin ba\u015far\u0131l\u0131 uygulanmas\u0131<\/td><td>%20<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Mevcut i\u015f trendlerine dayal\u0131 olarak en olas\u0131 senaryo, 2027'ye kadar y\u0131ll\u0131k %7-9 temett\u00fc b\u00fcy\u00fcmesi olan temel durumdur. Bu, \u00fc\u00e7 ayl\u0131k temett\u00fcy\u00fc mevcut 0.665 dolardan 2027'ye kadar yakla\u015f\u0131k 0.93-0.98 dolara \u00e7\u0131kararak, mevcut hisse fiyatlar\u0131nda %3.5-3.7'lik bir ileri getiri potansiyeli yaratabilir.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Yat\u0131r\u0131mc\u0131lar, CVS'nin temett\u00fc e\u011frisinin \u00f6nc\u00fc g\u00f6stergeleri olarak \u00fc\u00e7 ana metri\u011fi izlemelidir: 1) PBM s\u00f6zle\u015fme yenilemelerinde eczane geri \u00f6deme oranlar\u0131, 2) Aetna sigorta segmentindeki t\u0131bbi kay\u0131p oran\u0131 ve 3) dijital d\u00f6n\u00fc\u015f\u00fcm giri\u015fimleri i\u00e7in sermaye harcama seviyeleri. Bu metriklerdeki \u00f6nemli de\u011fi\u015fiklikler, genellikle temett\u00fc politikas\u0131ndaki de\u011fi\u015fikliklerden 2-3 \u00e7eyrek \u00f6nce gelir.<\/p><\/div>[cta_button text=\"\"]<div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Sonu\u00e7: CVS Temett\u00fc Yat\u0131r\u0131mlar\u0131ndan Maksimum Getiri Sa\u011flama<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi, hissedar getirilerine form\u00fclsel de\u011fil stratejik yakla\u015fan bir \u015firketi ortaya koyuyor. Yat\u0131r\u0131mc\u0131lar i\u00e7in bu, hem gelir hem de sermaye kazanc\u0131n\u0131 optimize etmek i\u00e7in d\u00fc\u015f\u00fcnceli pozisyon zamanlamas\u0131 ve boyutland\u0131rmas\u0131 yoluyla belirli f\u0131rsatlar yarat\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Mevcut yat\u0131r\u0131mc\u0131lar, g\u00fc\u00e7l\u00fc g\u00fcvenlik metrikleri ve y\u0131ll\u0131k %7-9 b\u00fcy\u00fcme potansiyeli ile %2.58'lik \u0131l\u0131ml\u0131 bir \u00e7ekici getiri elde ediyor. \u015eirketin muhafazakar %30 \u00f6deme oran\u0131, sa\u011fl\u0131k sekt\u00f6r\u00fc dalgalanmalar\u0131na kar\u015f\u0131 anlaml\u0131 bir koruma sa\u011flarken, stratejik yat\u0131r\u0131m a\u015famalar\u0131nda bile temett\u00fc b\u00fcy\u00fcmesine devam etmesine olanak tan\u0131r.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Optimal sonu\u00e7lar, CVS temett\u00fclerini ge\u00e7ici hisse fiyat\u0131 zay\u0131fl\u0131klar\u0131 s\u0131ras\u0131nda getiri geni\u015fleme f\u0131rsatlar\u0131ndan yararlanan toplam getiri \u00e7er\u00e7evesi i\u00e7inde g\u00f6rmekten gelir. Pocket Option'\u0131n temett\u00fc analiz ara\u00e7lar\u0131, yat\u0131r\u0131mc\u0131lara bu taktik giri\u015f noktalar\u0131n\u0131 belirlemelerine ve hem gelir hem de de\u011fer art\u0131\u015f\u0131 potansiyeli i\u00e7in pozisyon boyutland\u0131rmas\u0131n\u0131 optimize etmelerine yard\u0131mc\u0131 olabilir.<\/p><\/div>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>CVS Health&#8217;\u0131n Temett\u00fc Program\u0131n\u0131n Evrimi<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi, m\u00fctevaz\u0131 ba\u015flang\u0131\u00e7lardan 2024 y\u0131l\u0131na kadar hisse ba\u015f\u0131na 0.665 dolar\u0131 a\u015fan \u00fc\u00e7 ayl\u0131k \u00f6demelere d\u00f6n\u00fc\u015ferek yirmi y\u0131l\u0131 a\u015fk\u0131n bir s\u00fcreyi kaps\u0131yor. B\u00f6lgesel bir eczane zincirinden sa\u011fl\u0131k hizmetleri devine d\u00f6n\u00fc\u015fen \u015firketin yolculu\u011fu, hissedar getirilerine y\u00f6nelik geli\u015fen yakla\u015f\u0131m\u0131n\u0131 do\u011frudan yans\u0131t\u0131yor ve temett\u00fc yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in de\u011ferli bir vaka \u00e7al\u0131\u015fmas\u0131 haline geliyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>CVS, temett\u00fc \u00f6demelerini sat\u0131n almalar, bor\u00e7 y\u00f6netimi ve geni\u015fleme ile dengeleyerek sermaye tahsis stratejisindeki \u00f6nceliklerini ortaya koyuyor. Bu dengeli yakla\u015f\u0131m, CVS hisse senedi temett\u00fc getirisi e\u011filiminde, keyfi \u00f6deme politikalar\u0131ndan ziyade stratejik i\u015f kararlar\u0131n\u0131 yans\u0131tan belirgin a\u015famalar yaratm\u0131\u015ft\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option&#8217;daki finansal analistler, CVS&#8217;nin i\u015f modelindeki bu stratejik de\u011fi\u015fimlerin temett\u00fc ge\u00e7mi\u015findeki belirgin a\u015famalarla do\u011frudan ili\u015fkili oldu\u011funu belirtiyor. \u015eirketin eczane perakendecisinden entegre sa\u011fl\u0131k hizmeti sa\u011flay\u0131c\u0131s\u0131na d\u00f6n\u00fc\u015f\u00fcm\u00fc, \u00fc\u00e7 farkl\u0131 temett\u00fc d\u00f6nemi yaratm\u0131\u015ft\u0131r: b\u00fcy\u00fcme (2010-2016), konsolidasyon (2017-2021) ve \u00f6l\u00e7\u00fcl\u00fc geni\u015fleme (2022-g\u00fcn\u00fcm\u00fcz).<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Tarihsel Perspektif: CVS Temett\u00fc B\u00fcy\u00fcme E\u011frisi<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>2010 ve 2016 y\u0131llar\u0131 aras\u0131nda, CVS \u00fc\u00e7 ayl\u0131k temett\u00fcs\u00fcn\u00fc bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131 %24.8 ile 0.0875 dolardan hisse ba\u015f\u0131na 0.50 dolara \u00e7\u0131kard\u0131. Bu agresif b\u00fcy\u00fcme a\u015famas\u0131, \u015firketin d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc Aetna sat\u0131n al\u0131m\u0131n\u0131 ger\u00e7ekle\u015ftirirken temett\u00fcs\u00fcn\u00fc be\u015f y\u0131l boyunca \u00fc\u00e7 ayda bir 0.50 dolarda dondurdu\u011fu 2017 y\u0131l\u0131nda aniden sona erdi.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>D\u00f6nem<\/th>\n<th>Temett\u00fc Stratejisi<\/th>\n<th>CAGR<\/th>\n<th>Ana \u0130\u015f Olaylar\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2010-2016<\/td>\n<td>Agresif b\u00fcy\u00fcme<\/td>\n<td>%24.8<\/td>\n<td>Caremark entegrasyonu, perakende geni\u015fleme<\/td>\n<\/tr>\n<tr>\n<td>2017-2021<\/td>\n<td>\u00dc\u00e7 ayda bir 0.50 dolarda temett\u00fc dondurma<\/td>\n<td>%0<\/td>\n<td>69 milyar dolarl\u0131k Aetna sat\u0131n al\u0131m\u0131, bor\u00e7 azaltma odakl\u0131<\/td>\n<\/tr>\n<tr>\n<td>2022-2023<\/td>\n<td>Temett\u00fc b\u00fcy\u00fcmesinin yeniden ba\u015flamas\u0131<\/td>\n<td>%10.0<\/td>\n<td>Sat\u0131n alma sonras\u0131 entegrasyon, 9.8 milyar dolarl\u0131k bor\u00e7 azaltma<\/td>\n<\/tr>\n<tr>\n<td>2024-G\u00fcn\u00fcm\u00fcz<\/td>\n<td>Orta derecede b\u00fcy\u00fcme modeli<\/td>\n<td>%9.9<\/td>\n<td>Sa\u011fl\u0131k hizmeti sunum modeli d\u00f6n\u00fc\u015f\u00fcm\u00fc<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Be\u015f y\u0131ll\u0131k temett\u00fc dondurmas\u0131, do\u011frudan CVS&#8217;nin 2018&#8217;de Aetna&#8217;y\u0131 69 milyar dolara sat\u0131n almas\u0131yla \u00e7ak\u0131\u015ft\u0131. Bu d\u00f6nemde, CVS bilan\u00e7osunu hafifletmeye \u00f6ncelik vererek, borcunu yakla\u015f\u0131k 13.3 milyar dolar azalt\u0131rken hissedar \u00f6demelerini b\u00fcy\u00fctmek yerine korudu. Bu stratejik karar, entegrasyon d\u00f6neminde sermayeyi korudu\u011fu i\u00e7in mali a\u00e7\u0131dan ak\u0131ll\u0131ca oldu ve yat\u0131r\u0131mc\u0131 g\u00fcvenini zedeleyebilecek temett\u00fc kesintilerinden ka\u00e7\u0131n\u0131ld\u0131.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h3 class='po-article-page__title'>Son Temett\u00fc H\u0131zlanma A\u015famas\u0131<\/h3>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Ocak 2022&#8217;de, CVS temett\u00fc b\u00fcy\u00fcmesini \u00fc\u00e7 ayda bir %10 art\u0131\u015fla 0.55 dolara, ard\u0131ndan 2023&#8217;te %10 art\u0131\u015fla 0.605 dolara ve Ocak 2024&#8217;te %9.9 art\u0131\u015fla 0.665 dolara \u00e7\u0131kararak yeniden ba\u015flatt\u0131. Bu \u00fc\u00e7 y\u0131ll\u0131k h\u0131zlanma a\u015famas\u0131, daha \u00f6nce dondurulmu\u015f seviyeden %9.97 bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme sa\u011flad\u0131.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>\u00d6deme Tarihi<\/th>\n<th>Hisse Ba\u015f\u0131na Temett\u00fc ($)<\/th>\n<th>Y\u0131ll\u0131k Art\u0131\u015f (%)<\/th>\n<th>Son 12 Ayl\u0131k EPS Kapsam\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ocak 2022<\/td>\n<td>$0.55<\/td>\n<td>%10.0<\/td>\n<td>3.13x<\/td>\n<\/tr>\n<tr>\n<td>Ocak 2023<\/td>\n<td>$0.605<\/td>\n<td>%10.0<\/td>\n<td>3.02x<\/td>\n<\/tr>\n<tr>\n<td>Ocak 2024<\/td>\n<td>$0.665<\/td>\n<td>%9.9<\/td>\n<td>3.01x<\/td>\n<\/tr>\n<tr>\n<td>Beklenen Nisan 2025<\/td>\n<td>$0.67 (tahmini)<\/td>\n<td>~%0.75<\/td>\n<td>3.37x (tahmini)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>2025&#8217;te %0.75 b\u00fcy\u00fcmeye yava\u015flama, y\u00f6netimin eczane alan\u0131ndaki artan rekabet ve sa\u011fl\u0131k hizmetleri geri \u00f6deme bask\u0131lar\u0131 kar\u015f\u0131s\u0131nda temkinli g\u00f6r\u00fcn\u00fcm\u00fcn\u00fc yans\u0131t\u0131yor. 2023 4. \u00c7eyrek kazan\u00e7 \u00e7a\u011fr\u0131s\u0131nda, CFO Shawn Guertin, &#8220;belirsiz piyasa ko\u015fullar\u0131&#8221; ve &#8220;stratejik esneklik gereksinimleri&#8221;ni temett\u00fc b\u00fcy\u00fcme beklentilerini \u0131l\u0131ml\u0131la\u015ft\u0131rman\u0131n nedenleri olarak belirtti.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>CVS Hisse Senedi Temett\u00fc Getirisi Analizi: Ana Performans Metrikleri<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Mutlak temett\u00fc \u00f6demelerinin artmas\u0131na ra\u011fmen, CVS hisse senedi temett\u00fc getirisi, hisse fiyat\u0131 dalgalanmalar\u0131 nedeniyle 2019&#8217;da %3.81&#8217;den 2024&#8217;te %2.58&#8217;e d\u00fc\u015ft\u00fc. Bu ters ili\u015fki, ge\u00e7ici fiyat d\u00fc\u015f\u00fc\u015fleri s\u0131ras\u0131nda cazip giri\u015f noktalar\u0131n\u0131 belirleyebilen gelir yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in stratejik f\u0131rsatlar yarat\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Y\u0131l<\/th>\n<th>Ortalama Temett\u00fc Getirisi<\/th>\n<th>Hisse Fiyat\u0131 Aral\u0131\u011f\u0131<\/th>\n<th>Sekt\u00f6r Ortalama Getirisi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2019<\/td>\n<td>%3.81<\/td>\n<td>$52-$77<\/td>\n<td>%2.7<\/td>\n<\/tr>\n<tr>\n<td>2020<\/td>\n<td>%3.12<\/td>\n<td>$52-$76<\/td>\n<td>%2.9<\/td>\n<\/tr>\n<tr>\n<td>2022<\/td>\n<td>%2.31<\/td>\n<td>$88-$111<\/td>\n<td>%2.4<\/td>\n<\/tr>\n<tr>\n<td>2024 (G\u00fcncel)<\/td>\n<td>%2.58<\/td>\n<td>$58-$77<\/td>\n<td>%2.5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>CVS hisse senedi temett\u00fc getirisi, eczane geri \u00f6deme oranlar\u0131 ve perakende bozulma konusundaki piyasa endi\u015feleri hisse fiyatlar\u0131n\u0131 55 dolar\u0131n alt\u0131na d\u00fc\u015f\u00fcrd\u00fc\u011f\u00fcnde 2019&#8217;da %3.81 ile zirveye ula\u015ft\u0131. Bunu ge\u00e7ici bir de\u011ferleme kopuklu\u011fu olarak tan\u0131yan yat\u0131r\u0131mc\u0131lar, hem ortalaman\u0131n \u00fczerinde gelir hem de 2021 sonlar\u0131nda 100 dolar aral\u0131\u011f\u0131na geri d\u00f6nd\u00fc\u011f\u00fcnde sermaye kazanc\u0131 sa\u011flad\u0131.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option&#8217;\u0131n temett\u00fc izleme ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar, CVS&#8217;nin getirisi tarihsel ortalamas\u0131n\u0131n \u00f6nemli \u00f6l\u00e7\u00fcde \u00fczerine \u00e7\u0131kt\u0131\u011f\u0131nda, potansiyel olarak cazip bir giri\u015f noktas\u0131n\u0131 belirleyebilir. \u015eu anda, %2.58&#8217;lik getiri, \u015firketin 5 y\u0131ll\u0131k ortalama getirisi olan %3.11&#8217;in %17 alt\u0131nda, bu da mevcut fiyatlarda \u0131l\u0131ml\u0131 ancak \u00e7ekici olmayan bir gelir de\u011feri \u00f6neriyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Kar\u015f\u0131la\u015ft\u0131rmal\u0131 Analiz: CVS Temett\u00fc Politikas\u0131 ve Sekt\u00f6r E\u015fleri<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>CVS&#8217;nin temett\u00fc yakla\u015f\u0131m\u0131, Walgreens gibi y\u00fcksek getirili, yava\u015f b\u00fcy\u00fcyen \u015firketler ile UnitedHealth gibi d\u00fc\u015f\u00fck getirili, agresif b\u00fcy\u00fcme modelleri aras\u0131nda stratejik bir orta yol i\u015fgal ediyor. Bu konumland\u0131rma, CVS&#8217;nin perakende eczane, sigorta ve sa\u011fl\u0131k hizmetleri alanlar\u0131n\u0131 kapsayan hibrit i\u015f modelini yans\u0131t\u0131yor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>\u015eirket<\/th>\n<th>G\u00fcncel Temett\u00fc Getirisi<\/th>\n<th>5 Y\u0131ll\u0131k Temett\u00fc CAGR<\/th>\n<th>\u00d6deme Oran\u0131<\/th>\n<th>Temett\u00fc G\u00fcvenlik Skoru<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>CVS Health<\/td>\n<td>%2.58<\/td>\n<td>%5.9<\/td>\n<td>%30<\/td>\n<td>85\/100 (\u00c7ok G\u00fcvenli)<\/td>\n<\/tr>\n<tr>\n<td>Walgreens Boots Alliance<\/td>\n<td>%4.7<\/td>\n<td>%2.1<\/td>\n<td>%40<\/td>\n<td>55\/100 (G\u00fcvenli)<\/td>\n<\/tr>\n<tr>\n<td>UnitedHealth Group<\/td>\n<td>%1.6<\/td>\n<td>%15<\/td>\n<td>%33<\/td>\n<td>95\/100 (\u00c7ok G\u00fcvenli)<\/td>\n<\/tr>\n<tr>\n<td>Cardinal Health<\/td>\n<td>%1.9<\/td>\n<td>%1.3<\/td>\n<td>%36<\/td>\n<td>70\/100 (G\u00fcvenli)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>CVS, yakla\u015f\u0131k %30 kazan\u00e7 oran\u0131yla, e\u015f grubu aras\u0131nda en muhafazakar \u00f6deme oranlar\u0131ndan birini koruyor. Bu oran, \u015firketin i\u015f d\u00f6n\u00fc\u015f\u00fcm\u00fcne ra\u011fmen \u015fa\u015f\u0131rt\u0131c\u0131 derecede istikrarl\u0131 kalm\u0131\u015f olup, hissedar getirilerini yeniden yat\u0131r\u0131m ihtiya\u00e7lar\u0131yla dengeleme konusunda disiplinli bir yakla\u015f\u0131m\u0131 g\u00f6steriyor. Ba\u011flam i\u00e7in, sa\u011fl\u0131k sekt\u00f6r\u00fc ortalama \u00f6deme oran\u0131 %38&#8217;dir, bu da CVS&#8217;nin finansal kaynaklar\u0131n\u0131 zorlamadan temett\u00fc art\u0131\u015flar\u0131 i\u00e7in ek kapasiteye sahip oldu\u011funu g\u00f6steriyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>CVS Temett\u00fc Kararlar\u0131n\u0131 Etkileyen Stratejik Fakt\u00f6rler<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi, form\u00fclsel art\u0131\u015flar yerine belirli i\u015f zorluklar\u0131na ve f\u0131rsatlar\u0131na verilen kas\u0131tl\u0131 yan\u0131tlar\u0131 yans\u0131t\u0131r. Bu stratejik itici g\u00fc\u00e7leri anlamak, yat\u0131r\u0131mc\u0131lar\u0131n gelecekteki temett\u00fc eylemlerini, tarihsel b\u00fcy\u00fcme oranlar\u0131n\u0131n basit bir ekstrapolasyonundan daha do\u011fru bir \u015fekilde tahmin etmelerine yard\u0131mc\u0131 olur.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm article-content po-article-page__text'>\n<ul class='po-article-page-list'>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Serbest nakit ak\u0131\u015f\u0131 \u00fcretimi: CVS&#8217;nin eczane operasyonlar\u0131, 2023&#8217;te 12.7 milyar dolar i\u015fletme nakit ak\u0131\u015f\u0131 \u00fcreterek sa\u011flam temett\u00fc kapsam\u0131 sa\u011flad\u0131<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Entegrasyon yat\u0131r\u0131mlar\u0131: Aetna sat\u0131n al\u0131m\u0131, 2018-2021 aras\u0131nda 2.3 milyar dolar entegrasyon maliyeti gerektirdi ve do\u011frudan temett\u00fc b\u00fcy\u00fcme kapasitesini etkiledi<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Sa\u011fl\u0131k hizmetleri geri \u00f6deme bask\u0131lar\u0131: Eczane fayda s\u0131k\u0131\u015fmas\u0131, 2020&#8217;den bu yana re\u00e7ete ba\u015f\u0131na marjlar\u0131 yakla\u015f\u0131k %3.5 azaltt\u0131<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Dijital d\u00f6n\u00fc\u015f\u00fcm: Teknoloji modernizasyonuna 2.8 milyar dolarl\u0131k yat\u0131r\u0131m, temett\u00fc dolar\u0131 ile rekabet ediyor<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Bor\u00e7 azaltma \u00f6ncelikleri: Net bor\u00e7, sat\u0131n alma sonras\u0131 73.6 milyar dolardan 2023&#8217;te 51.4 milyar dolara d\u00fc\u015ft\u00fc<\/li>\n<\/ul>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>CVS hisse senedi temett\u00fc tarihindeki en \u00f6nemli d\u00f6nem, \u015firketin 69 milyar dolarl\u0131k Aetna sat\u0131n al\u0131m\u0131n\u0131 finanse etmek i\u00e7in temett\u00fc b\u00fcy\u00fcmesini tamamen durdurdu\u011fu 2017-2021 y\u0131llar\u0131 aras\u0131nda ger\u00e7ekle\u015fti. Bu be\u015f y\u0131ll\u0131k d\u00f6nemde, CVS bor\u00e7\/EBITDA oran\u0131n\u0131 4.7x&#8217;den 3.1x&#8217;e d\u00fc\u015f\u00fcr\u00fcrken temett\u00fcs\u00fcn\u00fc b\u00fcy\u00fctmek yerine korudu ve finansal istikrar\u0131 an\u0131nda hissedar getirilerinin \u00f6n\u00fcne koydu.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Stratejik Giri\u015fim<\/th>\n<th>Yat\u0131r\u0131lan Sermaye<\/th>\n<th>Temett\u00fc Etkisi<\/th>\n<th>Uzun Vadeli Temett\u00fc Faydas\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>MinuteClinic\/HealthHUB geni\u015flemesi<\/td>\n<td>$1.2 milyar<\/td>\n<td>~$0.03 temett\u00fc azaltma potansiyeli<\/td>\n<td>2026&#8217;ya kadar y\u0131ll\u0131k 0.6 milyar dolar ek kazan\u00e7<\/td>\n<\/tr>\n<tr>\n<td>Dijital sa\u011fl\u0131k yat\u0131r\u0131mlar\u0131<\/td>\n<td>$2.8 milyar<\/td>\n<td>~$0.07 temett\u00fc azaltma potansiyeli<\/td>\n<td>2025&#8217;e kadar y\u0131ll\u0131k 1.2 milyar dolar maliyet tasarrufu<\/td>\n<\/tr>\n<tr>\n<td>Eczane otomasyonu<\/td>\n<td>$1.4 milyar<\/td>\n<td>~$0.035 temett\u00fc azaltma potansiyeli<\/td>\n<td>2026&#8217;ya kadar %0.8 marj geni\u015flemesi<\/td>\n<\/tr>\n<tr>\n<td>Oak Street Health sat\u0131n al\u0131m\u0131<\/td>\n<td>$10.6 milyar<\/td>\n<td>~$0.25 temett\u00fc azaltma potansiyeli<\/td>\n<td>2026&#8217;ya kadar 2 milyar dolar ek EBITDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option&#8217;daki analistler, her stratejik giri\u015fimin k\u0131sa vadeli temett\u00fc kapasitesini uzun vadeli temett\u00fc b\u00fcy\u00fcme potansiyeline kar\u015f\u0131 nas\u0131l etkiledi\u011fini nicel olarak belirleyen \u00f6zel bir CVS Temett\u00fc Kapasite Modeli geli\u015ftirdiler. Bu model, mevcut stratejik yat\u0131r\u0131mlar\u0131n \u00f6ng\u00f6r\u00fclen getirilerini sa\u011flamas\u0131 durumunda CVS&#8217;nin 2027&#8217;ye kadar y\u0131ll\u0131k %7-9 oran\u0131nda temett\u00fcs\u00fcn\u00fc s\u00fcrd\u00fcr\u00fclebilir bir \u015fekilde art\u0131rabilece\u011fini \u00f6ne s\u00fcr\u00fcyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>CVS Temett\u00fc Modellerinden Yararlanan Yat\u0131r\u0131mc\u0131 Stratejileri<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi, farkl\u0131 yat\u0131r\u0131mc\u0131 profilleri i\u00e7in belirli f\u0131rsatlar yarat\u0131r. Tarihsel analiz, belirli taktik yakla\u015f\u0131mlar\u0131n pasif temett\u00fc toplama stratejilerini s\u00fcrekli olarak geride b\u0131rakt\u0131\u011f\u0131n\u0131 ortaya koyuyor.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm article-content po-article-page__text'>\n<ul class='po-article-page-list'>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Getiri tetikleyici giri\u015f noktalar\u0131: Getiri %3.25&#8217;i a\u015ft\u0131\u011f\u0131nda sat\u0131n almak, tarihsel olarak %15.3 ortalama y\u0131ll\u0131k toplam getiri sa\u011flam\u0131\u015ft\u0131r<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Dondurma sonras\u0131 h\u0131zlanma: Temett\u00fc dondurma d\u00f6nemlerinde b\u00fcy\u00fcme yeniden ba\u015flamadan \u00f6nce birikim yapmak (2022-2023&#8217;te %17.8 getiri)<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Temett\u00fc yeniden yat\u0131r\u0131m optimizasyonu: Otomatik yeniden yat\u0131r\u0131m yerine fiyat zay\u0131fl\u0131\u011f\u0131 s\u0131ras\u0131nda se\u00e7ici DRIP<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Sekt\u00f6r rotasyonu: CVS getirisini di\u011fer sa\u011fl\u0131k temett\u00fc \u00f6deyenlerle kar\u015f\u0131la\u015ft\u0131rarak g\u00f6receli de\u011feri belirlemek<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Stratejik ortalama: Getiri-b\u00fcy\u00fcme oran\u0131 %0.4&#8217;\u00fc a\u015ft\u0131\u011f\u0131nda \u00fc\u00e7 ayl\u0131k bazda pozisyonlar olu\u015fturmak<\/li>\n<\/ul>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Yat\u0131r\u0131mc\u0131 Profili<\/th>\n<th>Optimal Strateji<\/th>\n<th>Tarihsel Ba\u015far\u0131 \u00d6rne\u011fi<\/th>\n<th>Ana Zamanlama G\u00f6stergesi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gelir odakl\u0131 emekli<\/td>\n<td>Getiri tetikleyici al\u0131mlar<\/td>\n<td>Mart 2020: %3.8 getiri giri\u015f noktas\u0131<\/td>\n<td>Getiri &gt; %3.25<\/td>\n<\/tr>\n<tr>\n<td>B\u00fcy\u00fcme yat\u0131r\u0131mc\u0131s\u0131<\/td>\n<td>Temett\u00fc dondurma sonras\u0131 birikim<\/td>\n<td>2021 4. \u00c7eyrek: Temett\u00fc art\u0131\u015f\u0131 \u00f6ncesi konumland\u0131rma<\/td>\n<td>Y\u00f6netim temett\u00fc b\u00fcy\u00fcme sinyalleri<\/td>\n<\/tr>\n<tr>\n<td>De\u011fer yat\u0131r\u0131mc\u0131s\u0131<\/td>\n<td>Temett\u00fc b\u00fcy\u00fcmesine g\u00f6re fiyat\/kazan\u00e7<\/td>\n<td>2019: P\/E s\u0131k\u0131\u015f\u0131rken temett\u00fc sabit kald\u0131<\/td>\n<td>P\/E oran\u0131 5 y\u0131ll\u0131k ortalaman\u0131n alt\u0131nda<\/td>\n<\/tr>\n<tr>\n<td>Toplam getiri optimizasyoncusu<\/td>\n<td>Getiriye dayal\u0131 dinamik pozisyon boyutland\u0131rma<\/td>\n<td>60 dolar\u0131n alt\u0131nda pozisyonu ikiye katlad\u0131, 90 dolar\u0131n \u00fczerinde azaltt\u0131<\/td>\n<td>5 y\u0131ll\u0131k ortalamadan sapma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>\u00d6ng\u00f6r\u00fclebilir gelire odaklanan yat\u0131r\u0131mc\u0131lar i\u00e7in, CVS hisse senedi temett\u00fcleri genellikle Ocak, Nisan, Temmuz ve Ekim aylar\u0131n\u0131n sonlar\u0131nda d\u00fc\u015fen ex-temett\u00fc tarihleriyle \u00fc\u00e7 ayl\u0131k \u00f6demeler sunar. \u00d6n\u00fcm\u00fczdeki d\u00f6rt tahmini ex-temett\u00fc tarihi 24 Ekim 2024; 23 Ocak 2025; 24 Nisan 2025; ve 24 Temmuz 2025 olup, \u00f6deme tarihleri yakla\u015f\u0131k iki hafta sonrad\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Gelecek G\u00f6r\u00fcn\u00fcm\u00fc: CVS Temett\u00fc E\u011frisi<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Mevcut finansal metrikler, y\u00f6netim rehberli\u011fi ve CVS hisse senedi temett\u00fc ge\u00e7mi\u015findeki tarihsel kal\u0131plara dayanarak, \u00f6n\u00fcm\u00fczdeki 3-5 y\u0131l i\u00e7in CVS&#8217;nin temett\u00fc b\u00fcy\u00fcmesi i\u00e7in \u00fc\u00e7 potansiyel senaryo \u00f6ng\u00f6rebiliriz:<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Senaryo<\/th>\n<th>Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesi<\/th>\n<th>\u00d6zel Kataliz\u00f6rler<\/th>\n<th>Olas\u0131l\u0131k<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Temkinli Durum<\/td>\n<td>%3-5<\/td>\n<td>Eczane marj s\u0131k\u0131\u015fmas\u0131 &gt;%5, Medicare Advantage oran bask\u0131s\u0131<\/td>\n<td>%30<\/td>\n<\/tr>\n<tr>\n<td>Temel Durum<\/td>\n<td>%7-9<\/td>\n<td>Oak Street Health entegrasyonunun ba\u015far\u0131s\u0131, \u0131l\u0131ml\u0131 eczane faydalar\u0131n\u0131n istikrar\u0131<\/td>\n<td>%50<\/td>\n<\/tr>\n<tr>\n<td>Agresif Durum<\/td>\n<td>%10-12<\/td>\n<td>HealthHUB kar marj\u0131 %15&#8217;i a\u015farsa, de\u011fer bazl\u0131 bak\u0131m modelinin ba\u015far\u0131l\u0131 uygulanmas\u0131<\/td>\n<td>%20<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Mevcut i\u015f trendlerine dayal\u0131 olarak en olas\u0131 senaryo, 2027&#8217;ye kadar y\u0131ll\u0131k %7-9 temett\u00fc b\u00fcy\u00fcmesi olan temel durumdur. Bu, \u00fc\u00e7 ayl\u0131k temett\u00fcy\u00fc mevcut 0.665 dolardan 2027&#8217;ye kadar yakla\u015f\u0131k 0.93-0.98 dolara \u00e7\u0131kararak, mevcut hisse fiyatlar\u0131nda %3.5-3.7&#8217;lik bir ileri getiri potansiyeli yaratabilir.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Yat\u0131r\u0131mc\u0131lar, CVS&#8217;nin temett\u00fc e\u011frisinin \u00f6nc\u00fc g\u00f6stergeleri olarak \u00fc\u00e7 ana metri\u011fi izlemelidir: 1) PBM s\u00f6zle\u015fme yenilemelerinde eczane geri \u00f6deme oranlar\u0131, 2) Aetna sigorta segmentindeki t\u0131bbi kay\u0131p oran\u0131 ve 3) dijital d\u00f6n\u00fc\u015f\u00fcm giri\u015fimleri i\u00e7in sermaye harcama seviyeleri. Bu metriklerdeki \u00f6nemli de\u011fi\u015fiklikler, genellikle temett\u00fc politikas\u0131ndaki de\u011fi\u015fikliklerden 2-3 \u00e7eyrek \u00f6nce gelir.<\/p>\n<\/div>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\"><\/span>\n        <\/a>\n    <\/div>\n    \n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Sonu\u00e7: CVS Temett\u00fc Yat\u0131r\u0131mlar\u0131ndan Maksimum Getiri Sa\u011flama<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>CVS hisse senedi temett\u00fc ge\u00e7mi\u015fi, hissedar getirilerine form\u00fclsel de\u011fil stratejik yakla\u015fan bir \u015firketi ortaya koyuyor. Yat\u0131r\u0131mc\u0131lar i\u00e7in bu, hem gelir hem de sermaye kazanc\u0131n\u0131 optimize etmek i\u00e7in d\u00fc\u015f\u00fcnceli pozisyon zamanlamas\u0131 ve boyutland\u0131rmas\u0131 yoluyla belirli f\u0131rsatlar yarat\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Mevcut yat\u0131r\u0131mc\u0131lar, g\u00fc\u00e7l\u00fc g\u00fcvenlik metrikleri ve y\u0131ll\u0131k %7-9 b\u00fcy\u00fcme potansiyeli ile %2.58&#8217;lik \u0131l\u0131ml\u0131 bir \u00e7ekici getiri elde ediyor. \u015eirketin muhafazakar %30 \u00f6deme oran\u0131, sa\u011fl\u0131k sekt\u00f6r\u00fc dalgalanmalar\u0131na kar\u015f\u0131 anlaml\u0131 bir koruma sa\u011flarken, stratejik yat\u0131r\u0131m a\u015famalar\u0131nda bile temett\u00fc b\u00fcy\u00fcmesine devam etmesine olanak tan\u0131r.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Optimal sonu\u00e7lar, CVS temett\u00fclerini ge\u00e7ici hisse fiyat\u0131 zay\u0131fl\u0131klar\u0131 s\u0131ras\u0131nda getiri geni\u015fleme f\u0131rsatlar\u0131ndan yararlanan toplam getiri \u00e7er\u00e7evesi i\u00e7inde g\u00f6rmekten gelir. Pocket Option&#8217;\u0131n temett\u00fc analiz ara\u00e7lar\u0131, yat\u0131r\u0131mc\u0131lara bu taktik giri\u015f noktalar\u0131n\u0131 belirlemelerine ve hem gelir hem de de\u011fer art\u0131\u015f\u0131 potansiyeli i\u00e7in pozisyon boyutland\u0131rmas\u0131n\u0131 optimize etmelerine yard\u0131mc\u0131 olabilir.<\/p>\n<\/div>\n"},"faq":[{"question":"CVS ne s\u0131kl\u0131kla temett\u00fc \u00f6der?","answer":"CVS Health, genellikle \u015eubat, May\u0131s, A\u011fustos ve Kas\u0131m aylar\u0131nda \u00f6demelerle \u00fc\u00e7 ayda bir temett\u00fc \u00f6der. Temett\u00fc tarihleri genellikle Ocak, Nisan, Temmuz ve Ekim aylar\u0131n\u0131n sonlar\u0131na denk gelir. Bu tutarl\u0131 \u00fc\u00e7 ayl\u0131k program, gelir yat\u0131r\u0131mc\u0131lar\u0131n\u0131n nakit ak\u0131\u015flar\u0131n\u0131 g\u00fcvenle planlamalar\u0131na olanak tan\u0131r."},{"question":"Mevcut CVS temett\u00fc getirisi nedir?","answer":"2024'\u00fcn ba\u015f\u0131 itibar\u0131yla, CVS Health hisse ba\u015f\u0131na 0.665 $'l\u0131k \u00fc\u00e7 ayl\u0131k \u00f6deme temelinde yakla\u015f\u0131k %2.58'lik bir temett\u00fc getirisi sunmaktad\u0131r. Bu getiri, sa\u011fl\u0131k sekt\u00f6r\u00fcnde rekabet\u00e7idir ve S&P 500 ortalama getirisi olan yakla\u015f\u0131k %1.5'ten \u00f6nemli \u00f6l\u00e7\u00fcde daha y\u00fcksektir, bu da onu gelir odakl\u0131 portf\u00f6yler i\u00e7in \u00e7ekici k\u0131lmaktad\u0131r."},{"question":"CVS hi\u00e7 temett\u00fcs\u00fcn\u00fc kesti mi?","answer":"Hay\u0131r, CVS Health yak\u0131n tarihte temett\u00fcs\u00fcn\u00fc kesmedi. \u015eirket, Aetna'n\u0131n sat\u0131n al\u0131nmas\u0131 ve entegrasyonu s\u0131ras\u0131nda 2017'den 2021'e kadar hisse ba\u015f\u0131na 0,50 $'l\u0131k sabit bir \u00fc\u00e7 ayl\u0131k temett\u00fc s\u00fcrd\u00fcrd\u00fc, \u00f6demeyi azaltmak yerine. 2022'den bu yana, CVS temett\u00fc art\u0131\u015f\u0131na devam etti ve s\u0131ras\u0131yla 0,55 $, ard\u0131ndan 0,605 $ ve en son olarak hisse ba\u015f\u0131na 0,665 $'a y\u00fckseltti."},{"question":"CVS'nin temett\u00fcs\u00fc di\u011fer sa\u011fl\u0131k \u015firketleriyle nas\u0131l kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131r?","answer":"CVS, sa\u011fl\u0131k sekt\u00f6r\u00fcnde orta d\u00fczeyde bir getiri pozisyonu sunmaktad\u0131r. UnitedHealth Group'tan (~%1.6) daha y\u00fcksek, ancak Walgreens Boots Alliance'tan (~%4.7) daha d\u00fc\u015f\u00fck bir getiri sa\u011flamaktad\u0131r. Bununla birlikte, CVS, Walgreens'e k\u0131yasla daha iyi temett\u00fc b\u00fcy\u00fcme s\u00fcrd\u00fcr\u00fclebilirli\u011fi g\u00f6stermi\u015ftir ve yakla\u015f\u0131k %30'luk muhafazakar bir \u00f6deme oran\u0131n\u0131 koruyarak gelecekteki art\u0131\u015flar i\u00e7in alan b\u0131rakmaktad\u0131r."},{"question":"Gelecekteki CVS temett\u00fc art\u0131\u015flar\u0131n\u0131 etkileyebilecek fakt\u00f6rler nelerdir?","answer":"CVS'nin gelecekteki temett\u00fc e\u011filimini etkileyebilecek birka\u00e7 fakt\u00f6r bulunmaktad\u0131r; bunlar aras\u0131nda sa\u011fl\u0131k hizmetleri d\u00fczenlemelerindeki de\u011fi\u015fiklikler, eczane geri \u00f6deme bask\u0131lar\u0131, son sat\u0131n almalar\u0131n entegrasyon ba\u015far\u0131s\u0131, bor\u00e7 azaltma ilerlemesi ve \u015firketin sa\u011fl\u0131k hizmetleri sunum d\u00f6n\u00fc\u015f\u00fcm\u00fc i\u00e7in sermaye gereksinimleri yer almaktad\u0131r. Ayr\u0131ca, daha geni\u015f ekonomik ko\u015fullar ve faiz oran\u0131 ortamlar\u0131, CVS'nin temett\u00fcs\u00fcn\u00fcn sabit gelirli alternatiflere k\u0131yasla g\u00f6receli \u00e7ekicili\u011fini etkileyecektir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"CVS ne s\u0131kl\u0131kla temett\u00fc \u00f6der?","answer":"CVS Health, genellikle \u015eubat, May\u0131s, A\u011fustos ve Kas\u0131m aylar\u0131nda \u00f6demelerle \u00fc\u00e7 ayda bir temett\u00fc \u00f6der. Temett\u00fc tarihleri genellikle Ocak, Nisan, Temmuz ve Ekim aylar\u0131n\u0131n sonlar\u0131na denk gelir. Bu tutarl\u0131 \u00fc\u00e7 ayl\u0131k program, gelir yat\u0131r\u0131mc\u0131lar\u0131n\u0131n nakit ak\u0131\u015flar\u0131n\u0131 g\u00fcvenle planlamalar\u0131na olanak tan\u0131r."},{"question":"Mevcut CVS temett\u00fc getirisi nedir?","answer":"2024'\u00fcn ba\u015f\u0131 itibar\u0131yla, CVS Health hisse ba\u015f\u0131na 0.665 $'l\u0131k \u00fc\u00e7 ayl\u0131k \u00f6deme temelinde yakla\u015f\u0131k %2.58'lik bir temett\u00fc getirisi sunmaktad\u0131r. Bu getiri, sa\u011fl\u0131k sekt\u00f6r\u00fcnde rekabet\u00e7idir ve S&P 500 ortalama getirisi olan yakla\u015f\u0131k %1.5'ten \u00f6nemli \u00f6l\u00e7\u00fcde daha y\u00fcksektir, bu da onu gelir odakl\u0131 portf\u00f6yler i\u00e7in \u00e7ekici k\u0131lmaktad\u0131r."},{"question":"CVS hi\u00e7 temett\u00fcs\u00fcn\u00fc kesti mi?","answer":"Hay\u0131r, CVS Health yak\u0131n tarihte temett\u00fcs\u00fcn\u00fc kesmedi. \u015eirket, Aetna'n\u0131n sat\u0131n al\u0131nmas\u0131 ve entegrasyonu s\u0131ras\u0131nda 2017'den 2021'e kadar hisse ba\u015f\u0131na 0,50 $'l\u0131k sabit bir \u00fc\u00e7 ayl\u0131k temett\u00fc s\u00fcrd\u00fcrd\u00fc, \u00f6demeyi azaltmak yerine. 2022'den bu yana, CVS temett\u00fc art\u0131\u015f\u0131na devam etti ve s\u0131ras\u0131yla 0,55 $, ard\u0131ndan 0,605 $ ve en son olarak hisse ba\u015f\u0131na 0,665 $'a y\u00fckseltti."},{"question":"CVS'nin temett\u00fcs\u00fc di\u011fer sa\u011fl\u0131k \u015firketleriyle nas\u0131l kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131r?","answer":"CVS, sa\u011fl\u0131k sekt\u00f6r\u00fcnde orta d\u00fczeyde bir getiri pozisyonu sunmaktad\u0131r. UnitedHealth Group'tan (~%1.6) daha y\u00fcksek, ancak Walgreens Boots Alliance'tan (~%4.7) daha d\u00fc\u015f\u00fck bir getiri sa\u011flamaktad\u0131r. Bununla birlikte, CVS, Walgreens'e k\u0131yasla daha iyi temett\u00fc b\u00fcy\u00fcme s\u00fcrd\u00fcr\u00fclebilirli\u011fi g\u00f6stermi\u015ftir ve yakla\u015f\u0131k %30'luk muhafazakar bir \u00f6deme oran\u0131n\u0131 koruyarak gelecekteki art\u0131\u015flar i\u00e7in alan b\u0131rakmaktad\u0131r."},{"question":"Gelecekteki CVS temett\u00fc art\u0131\u015flar\u0131n\u0131 etkileyebilecek fakt\u00f6rler nelerdir?","answer":"CVS'nin gelecekteki temett\u00fc e\u011filimini etkileyebilecek birka\u00e7 fakt\u00f6r bulunmaktad\u0131r; bunlar aras\u0131nda sa\u011fl\u0131k hizmetleri d\u00fczenlemelerindeki de\u011fi\u015fiklikler, eczane geri \u00f6deme bask\u0131lar\u0131, son sat\u0131n almalar\u0131n entegrasyon ba\u015far\u0131s\u0131, bor\u00e7 azaltma ilerlemesi ve \u015firketin sa\u011fl\u0131k hizmetleri sunum d\u00f6n\u00fc\u015f\u00fcm\u00fc i\u00e7in sermaye gereksinimleri yer almaktad\u0131r. Ayr\u0131ca, daha geni\u015f ekonomik ko\u015fullar ve faiz oran\u0131 ortamlar\u0131, CVS'nin temett\u00fcs\u00fcn\u00fcn sabit gelirli alternatiflere k\u0131yasla g\u00f6receli \u00e7ekicili\u011fini etkileyecektir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T14:16:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi\",\"datePublished\":\"2025-07-14T14:16:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/\"},\"wordCount\":18,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp\",\"keywords\":[\"investment\",\"stock\",\"strategy\"],\"articleSection\":[\"Data\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/\",\"name\":\"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp\",\"datePublished\":\"2025-07-14T14:16:42+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/","og_locale":"tr_TR","og_type":"article","og_title":"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-14T14:16:42+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi","datePublished":"2025-07-14T14:16:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/"},"wordCount":18,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp","keywords":["investment","stock","strategy"],"articleSection":["Data"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/","name":"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp","datePublished":"2025-07-14T14:16:42+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742025050644-700632539-8.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/cvs-stock-dividend-history\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"CVS Hisse Temett\u00fc Ge\u00e7mi\u015fi: Uzun Vadeli Yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00fcvenilir Gelir Stratejisi"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":305483,"slug":"cvs-stock-dividend-history","post_title":"L\u1ecbch S\u1eed C\u1ed5 T\u1ee9c C\u1ed5 Phi\u1ebfu CVS: Chi\u1ebfn L\u01b0\u1ee3c Thu Nh\u1eadp \u0110\u00e1ng Tin C\u1eady Cho Nh\u00e0 \u0110\u1ea7u T\u01b0 D\u00e0i H\u1ea1n","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/data\/cvs-stock-dividend-history\/"},"pt_AA":{"locale":"pt_AA","id":305478,"slug":"cvs-stock-dividend-history","post_title":"Hist\u00f3rico de Dividendos das A\u00e7\u00f5es da CVS: Estrat\u00e9gia de Renda Confi\u00e1vel para Investidores de Longo Prazo","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/data\/cvs-stock-dividend-history\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/305481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=305481"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/305481\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/250024"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=305481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=305481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=305481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}